TherapeuticsMD, Inc. (TXMD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TherapeuticsMD, Inc., a Nevada corporation, on July 7, 2023. The report discloses a material change in the Company's independent registered public accounting firm.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. However, it notes that the outgoing auditor, Grant Thornton LLP, included an explanatory paragraph in its reports for the fiscal years ended December 31, 2022, and December 31, 2021, describing the uncertainty regarding the Company's ability to continue as a going concern.
Material Changes
- Accountant Change: On July 7, 2023, the Audit Committee dismissed Grant Thornton LLP and engaged Berkowitz Pollack Brant (BPB) as the new independent registered public accounting firm for the 2023 fiscal year.
- Reason for Change: The decision resulted from a request for proposal process.
- Audit History: There were no disagreements with Grant Thornton LLP regarding accounting principles, practices, financial statement disclosures, or auditing scope/procedures during the 2021 and 2022 fiscal years or the subsequent period through dismissal.
- Reportable Events: No reportable events occurred under Item 304(a)(1)(v) of Regulation S-K during the relevant periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the previously disclosed going concern uncertainty. The Company confirmed that no consultations were held with the new auditor, BPB, regarding accounting principles, audit opinions, or reportable events prior to their engagement.
Investor Verification Checklist
- Verify the status of the Company's going concern uncertainty as highlighted in the 2021 and 2022 audit reports.
- Review the attached letter from Grant Thornton LLP (Exhibit 16.1) to confirm their agreement with the Company's statements regarding the dismissal.
- Monitor upcoming financial filings to assess the impact of the auditor change on the 2023 fiscal year audit process.
- Check for any subsequent filings regarding the Company's liquidity position and ability to meet operational obligations.